Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Medivir out-licenses hep C drug to China’s Ascletis; Cellectis launches pioneering UCART123 US study
Medivir out-licenses hep C drug to China’s Ascletis; Cellectis launches pioneering UCART123 US study
Medivir out-licenses hep C drug to China’s Ascletis; Cellectis launches pioneering UCART123 US study
Submitted by
admin
on August 19, 2017 - 10:29am
Source:
Endpoints
News Tags:
Medvir
hepatitis C
China
Ascletis
Cellectis
UCART123
CAR-T
Headline:
Medivir out-licenses hep C drug to China’s Ascletis; Cellectis launches pioneering UCART123 US study
Do Not Allow Advertisers to Use My Personal information
